The stock may face downward pressure despite revenue growth, as the large EPS miss and widening losses overshadow top-line gains. Investors should monitor management's ability to achieve cost savings and cash flow positivity by year-end as promised.
Price Chart
Executive Summary
Vivos Therapeutics reported full-year 2025 revenue of $17.4 million, up 16% YoY, driven by sleep testing services and integration of The Sleep Center of Nevada, but missed EPS consensus by 1.4% with a net loss of $21.2 million. Despite gross margin stability at 60%, elevated operating expenses from integration efforts widened losses significantly.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue: $17.4 million, up 16% YoY from $15.0 million in 2024
- EPS reported at -$2.07 vs. consensus estimate of -$0.48, a significant miss
- Gross margin held steady at 60%, but operating loss widened to $19.9 million from $11.2 million in 2024
- Operating expenses surged to $30.4 million from $20.2 million, driven by SCN integration costs
- Cash and cash equivalents declined to $2.0 million as of year-end, though $6.8 million in post-year financing was secured
Financial Impact
Revenue increased by $2.4 million, but net loss nearly doubled to $21.2 million due to integration costs and higher operating expenses
Risk Factors
- Continued cash burn and low cash balance ($2.0M) raise liquidity concerns
- Failure to achieve promised cost savings or cash flow breakeven could trigger further investor skepticism
- Dependence on recent financings raises dilution or listing compliance risks
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3274908 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 8-K | $0.1347 | awaiting T+60 | — | $0.1271 (−5.64%) |
Oct 19, 2026 7d ago | Press Release | $0.1410 | awaiting T+60 | — | $0.1271 (−9.86%) |
Oct 19, 2026 7d ago | 8-K | $0.1406 | awaiting T+60 | — | $0.1271 (−9.60%) |
Oct 15, 2026 12d ago | 8-K | $0.1428 | awaiting T+60 | — | $0.1271 (−10.99%) |
Oct 15, 2026 12d ago | Press Release | $0.1428 | awaiting T+60 | — | $0.1271 (−10.99%) |
Sep 30, 2026 26d ago | 8-K | $0.1490 | awaiting T+60 | — | $0.1271 (+14.70%) |
Aug 28, 2026 8w ago | Press Release | $0.2249 | awaiting T+60 | — | $0.1271 (−43.49%) |
Aug 21, 2026 9w ago | 8-K | $0.2768 | awaiting T+60 | — | $0.1271 (−54.08%) |
Aug 14, 2026 10w ago | Press Release | $0.3012 | awaiting T+60 | — | $0.1271 (+57.80%) |
Aug 14, 2026 10w ago | Press Release | $0.3433 | awaiting T+60 | — | $0.1271 (−62.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers